The Classic Egg-Yolk Macular Dystrophy of Childhood
A bruise rarely stays one colour for long — it moves through a fairly predictable sequence, from an initial deep mark to shades of purple, green, and yellow, before finally fading back to nothing. Best disease follows a similarly staged path beneath the macula: a rounded, golden-yellow deposit starts out smooth and whole, gradually breaks apart over a period of years, and eventually settles into its final form. The name vitelliform, borrowed from Latin, simply describes what that early deposit looks like — an egg yolk — and it's this whole staged process, more than any single symptom, that shapes how the condition is followed over time.
One detail regularly catches Zimbabwean families off guard at a first consultation: a child can carry a strikingly visible lesion on examination and still read comfortably at their expected level. Lesion appearance and actual vision simply don't always track together, which is exactly why correctly staging the disease matters far more than reacting to how dramatic a retinal photograph looks.
Vision holds up remarkably well for as long as the deposit stays whole, and it isn't unusual for a child to see almost perfectly despite an obvious finding on examination. Trouble tends to set in once that neat shape starts breaking apart, a phase people sometimes compare to a cracked egg, and reading small text becomes noticeably harder around this point, with central vision growing blurred or slightly distorted. Later on, once things settle into a more fixed pattern, the loss of central vision generally stays put rather than fluctuating further, though a small number of patients experience an additional, sudden dip if unwanted new blood vessels start forming beneath the retina.
A defect in the BEST1 gene sits behind this condition — under ordinary circumstances, this gene builds bestrophin-1, a protein that governs how ions and fluid pass across the retinal pigment epithelium. Once that process falters, fluid and pigment start pooling in the wrong place beneath the macula, gradually forming into the lesion seen on a scan. It's passed down as a dominant trait, yet its effects are anything but predictable — one carrier might have an obvious lesion and feel completely fine, while a close relative with the identical mutation ends up with real, noticeable trouble seeing.
Checking the eye's electro-oculogram is usually what settles the question, since the result reliably comes back low — an abnormal Arden ratio — even when a plain ERG taken from the same eye looks perfectly unremarkable. That contradiction between the two readings is precisely what steers a specialist toward Best disease rather than something that merely resembles it on the surface. Repeated OCT scans, spaced out over several visits, trace how far the lesion has actually progressed, and a positive BEST1 result both locks in the diagnosis and flags which relatives are worth screening for the same fault.
Since this particular lesion is entirely capable of sitting unchanged for years, doctors usually favour patient observation over rushing into treatment, all while staying alert to the modest possibility of abnormal vessel growth as things slowly progress. It's only once vision has genuinely begun slipping that regenerative stem cell therapy becomes a serious talking point, aimed at protecting whatever central vision is still doing its job.
That's entirely possible, and it's actually a familiar pattern in the early stage of Best disease. A lesion's size on a scan tells us surprisingly little about how well someone can actually see, which is why we lean on proper staging rather than reacting to a dramatic-looking image.
Not at all — this stays entirely confined to the retina and has zero connection to cancer of any kind. It does, however, move through a recognised sequence of stages over time, and tracking that sequence is exactly what our ongoing monitoring is there to do.
That's a classic case of variable expressivity, something BEST1 mutations are particularly known for. He may well be carrying the identical faulty gene without any lesion or symptom ever appearing — testing is really the only reliable way to confirm this, rather than assuming he simply escaped it.
Far from unavoidable — plenty of patients keep solid central vision for decades, especially when their particular lesion never advances beyond its earliest stage. Given how differently this plays out between individuals, ongoing monitoring is what lets us react quickly the moment anything genuinely changes.